Differences of the hypoxia driven gene response in small (H69) and nonsmall (H23) cell lung carcinomas

F. Rose, P. Mahlik, B. Reichmann, D. Giannakakis, R. Vosswinkel, J. Appel, S. Krick, R. Schermuly, F. Grimminger, W. Seeger, J. Hanze (Giessen, Germany)

Source: Annual Congress 2001 - Genetics and cell biology of lung cancer
Session: Genetics and cell biology of lung cancer
Session type: Oral Presentation
Number: 234

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
F. Rose, P. Mahlik, B. Reichmann, D. Giannakakis, R. Vosswinkel, J. Appel, S. Krick, R. Schermuly, F. Grimminger, W. Seeger, J. Hanze (Giessen, Germany). Differences of the hypoxia driven gene response in small (H69) and nonsmall (H23) cell lung carcinomas. Eur Respir J 2001; 16: Suppl. 31, 234

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Expression of RASGRF2 in non-small cell lung cancer and its effect of transfection on biological behavior of human NSCLC lines H1299
Source: Annual Congress 2012 - New aspects of lung cancer biology
Year: 2012

Adaptation to hypoxia leads to apoptosis resistance to cisplatin in non-small cell lung cancer (NSCLC) cell line
Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology
Year: 2008


HIF-1α modulation by topoisomerase inhibitors in A549, a non-small cell lung cancer cell line
Source: Annual Congress 2007 - Biology in thoracic oncology
Year: 2007


Choice of endogenous control for gene expression in nonsmall cell lung cancer
Source: Eur Respir J 2005; 26: 1002-1008
Year: 2005



Specific plasmids encoding shRNA molecules directed against growth factor receptors in cell proliferation inhibition and induction phenotype changes relevant to enhancement of anti-tumor immunity. Model of human non-small (NSCLC) and small (SCLC) cell lung cancer lines
Source: Annual Congress 2010 - Pathology of lung cancer
Year: 2010

Cyclooxygenase(COX)-2 is over-expressed in non small cell lung cancer (NSCLC) and is a potential target for treatment
Source: Eur Respir J 2002; 20: Suppl. 38, 400s
Year: 2002

Humanized S.typhi flagellin (FliC) transfected non-small cell lung cancer (NSCLC) cells induce local inflammatory and necrotic changes in an experimental model
Source: Annual Congress 2011 - Phagocytes and dendritic cells
Year: 2011

Expression of Fhit protein in non-small cell lung cancer (NSCLC) and its correlation with Ki-67, a proliferative marker
Source: Eur Respir J 2002; 20: Suppl. 38, 230s
Year: 2002

24h-blood profile gene expression biomarkers of the response to bevacizumab-erlotinib (BE) in advanced non-squamous non-small cell lung cancer (NSCLC)
Source: International Congress 2016 – Therapeutic trials in lung cancer
Year: 2016

FGFR1 gene aberrations and FGFR1 protein expression in squamous non-small cell lung cancer (Sq-NSCLC).
Source: Virtual Congress 2021 – Biology of lung cancer: preclinical and translational research
Year: 2021


Characterization of patients with non-small cell lung cancer (NSCLC) relative to its EGFR mutational status
Source: Annual Congress 2011 - Epidemiology of lung cancer and screening
Year: 2011


Investigation of survivin gene polymorphism in non-small cell lung cancer patients (NSCLC)
Source: Annual Congress 2012 - New biomarkers for lung cancer
Year: 2012


XAGE-1b and p53: Potential targets for immunotherapy of non-small cell lung cancer (NSCLC)
Source: Annual Congress 2012 - Treatment of lung cancer
Year: 2012

Investigation of a relationship between NF-KB1A gene polymorphism and non small cell lung cancer (NSCLC)
Source: Annual Congress 2012 - New biomarkers for lung cancer
Year: 2012

Prognostic value of apoptotic index (AI) considered jointly with cell cycle regulators in non-small cell lung cancer (NSCLC)
Source: Eur Respir J 2006; 28: Suppl. 50, 387s
Year: 2006

LATE-BREAKING ABSTRACT: Expression of macrophage migration inhibitory factor (MIF) in the serum and lung tissues in patients with non-small cell lung cancer (NSCLC)
Source: Annual Congress 2012 - Prognosis of lung cancer
Year: 2012

Bevacizumab (Avastin®) aerosol therapy (AT) inhibits primary and metastatic tumor growth in a murine model with human non-small cell lung cancer (NSCLC)
Source: Annual Congress 2012 - Treatment of lung cancer
Year: 2012


Impact of PD-L1 expression levels on the response to pembrolizumab in metastatic non-small cell lung cancer>
Source: Virtual Congress 2021 – Screening, diagnosis, management and prognosis of lung cancer
Year: 2021


Survivin expression in non-small cell lung cancer
Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases
Year: 2010

Polymorphisms in the interleukin-10 gene promoter are associated with susceptibility to non-small cell lung cancer (NSCLC)
Source: Eur Respir J 2005; 26: Suppl. 49, 458s
Year: 2005